Literature DB >> 18502268

Does insulin resistance, visceral adiposity, or a sex hormone alteration underlie the metabolic syndrome? Studies in women.

Gerald B Phillips1, Tianyi Jing, Steven B Heymsfield.   

Abstract

Insulin resistance, obesity, and a sex hormone alteration have each been suggested as the underlying link for the constellation of risk factors for myocardial infarction (MI) commonly referred to as the metabolic syndrome or the insulin resistance syndrome. In an attempt to identify in women which of these variables is the most likely link, insulin, adiposity variables, sex hormones, and risk factors for MI were measured and their relationships analyzed statistically in 58 premenopausal and 20 postmenopausal healthy women. On controlling for age, visceral adipose tissue (VAT) correlated more strongly with risk factors for MI, insulin, and free testosterone (FT) than did total adipose tissue or subcutaneous adipose tissue. VAT, therefore, was used as the adiposity variable for further data analysis. Waist circumference was a better surrogate of VAT than was waist-hip ratio, which was a poor surrogate of VAT. VAT correlated positively with insulin, FT, triglyceride, and glucose, and negatively with high-density lipoprotein and sex hormone-binding globulin. On controlling for age, FT and insulin correlated with risk factors for MI and with each other, but on controlling for age and VAT, all of their correlations lost statistical significance except for FT-triglyceride and FT-insulin in the postmenopausal women. In conclusion, VAT accumulation in women, independently of other measures of adiposity, may largely explain the correlations of insulin, obesity, and sex hormones with risk factors for MI and may be the immediate underlying factor that links risk factors for MI to form the metabolic syndrome. Insulin resistance, which has been generally accepted to be the underlying factor, may be a component of the syndrome rather than its underlying link. We hypothesize that in women FT may effect preferential VAT accumulation and induce insulin resistance directly, as well as via VAT accumulation, so that a sex hormone alteration may underlie VAT accumulation and thus ultimately underlie the metabolic syndrome (with insulin resistance as a component).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502268      PMCID: PMC2507726          DOI: 10.1016/j.metabol.2008.01.029

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  47 in total

1.  Volume estimates by imaging methods: model comparisons with visible woman as the reference.

Authors:  Wei Shen; ZiMian Wang; Haiying Tang; Stanley Heshka; Mark Punyanitya; Shankuan Zhu; Jianbo Lei; Steven B Heymsfield
Journal:  Obes Res       Date:  2003-02

2.  The GILHT-E Syndrome?

Authors:  Gerald B Phillips
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

3.  Low sex hormone-binding globulin is associated with the metabolic syndrome in postmenopausal women.

Authors:  Melissa E Weinberg; JoAnn E Manson; Julie E Buring; Nancy R Cook; Ellen W Seely; Paul M Ridker; Kathryn M Rexrode
Journal:  Metabolism       Date:  2006-11       Impact factor: 8.694

Review 4.  Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation.

Authors:  Y Liu; J Ding; T L Bush; J C Longenecker; F J Nieto; S H Golden; M Szklo
Journal:  Am J Epidemiol       Date:  2001-09-15       Impact factor: 4.897

5.  The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study.

Authors:  Seija Korhonen; Maritta Hippeläinen; Mauno Vanhala; Seppo Heinonen; Leo Niskanen
Journal:  Fertil Steril       Date:  2003-06       Impact factor: 7.329

6.  Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

Authors:  David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Veli-Pekka Valkonen; Riitta Salonen; Jukka T Salonen
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

7.  Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome.

Authors:  Darcy B Carr; Kristina M Utzschneider; Rebecca L Hull; Keiichi Kodama; Barbara M Retzlaff; John D Brunzell; Jane B Shofer; Brian E Fish; Robert H Knopp; Steven E Kahn
Journal:  Diabetes       Date:  2004-08       Impact factor: 9.461

8.  Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.

Authors:  Alessandra Gambineri; Carla Pelusi; Silvia Genghini; Antonio Maria Morselli-Labate; Mauro Cacciari; Uberto Pagotto; Renato Pasquali
Journal:  Clin Endocrinol (Oxf)       Date:  2004-02       Impact factor: 3.478

9.  Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease.

Authors:  Samuel Klein; Luigi Fontana; V Leroy Young; Andrew R Coggan; Charles Kilo; Bruce W Patterson; B Selma Mohammed
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

10.  Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction.

Authors:  Gerald B Phillips; Tianyi Jing; Steven B Heymsfield
Journal:  Metabolism       Date:  2003-06       Impact factor: 8.694

View more
  19 in total

1.  Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program.

Authors:  Catherine Kim; Sherita Hill Golden; Kieren J Mather; Gail A Laughlin; Shengchun Kong; Bin Nan; Elizabeth Barrett-Connor; John F Randolph
Journal:  J Clin Endocrinol Metab       Date:  2012-08-09       Impact factor: 5.958

Review 2.  Ovarian hormones and obesity.

Authors:  Brigitte Leeners; Nori Geary; Philippe N Tobler; Lori Asarian
Journal:  Hum Reprod Update       Date:  2017-05-01       Impact factor: 15.610

3.  Endogenous sex hormone changes in postmenopausal women in the diabetes prevention program.

Authors:  Catherine Kim; Shengchun Kong; Gail A Laughlin; Sherita H Golden; Kieren J Mather; Bin Nan; Sharon L Edelstein; John F Randolph; Fernand Labrie; Elizabeth Buschur; Elizabeth Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2012-06-11       Impact factor: 5.958

Review 4.  Sex differences in the physiology of eating.

Authors:  Lori Asarian; Nori Geary
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-31       Impact factor: 3.619

5.  Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity.

Authors:  Nicole H Rogers; James W Perfield; Katherine J Strissel; Martin S Obin; Andrew S Greenberg
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

6.  Risk factors for idiopathic intracranial hypertension in men: a case-control study.

Authors:  J Alexander Fraser; Beau B Bruce; Janet Rucker; Lisa-Ann Fraser; Edward J Atkins; Nancy J Newman; Valérie Biousse
Journal:  J Neurol Sci       Date:  2009-11-30       Impact factor: 3.181

7.  Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study.

Authors:  Imke Janssen; Lynda H Powell; Rasa Kazlauskaite; Sheila A Dugan
Journal:  Obesity (Silver Spring)       Date:  2009-08-20       Impact factor: 5.002

8.  Greater short-term weight loss in women 20-45 versus 55-65 years of age following bariatric surgery.

Authors:  Christopher N Ochner; Julio Teixeira; Nori Geary; Lori Asarian
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

9.  Relevance of low testosterone to non-alcoholic fatty liver disease.

Authors:  Avni Mody; Donna White; Fasiha Kanwal; Jose M Garcia
Journal:  Cardiovasc Endocrinol       Date:  2015-09-01

10.  The effects of high fat diet and estradiol on hypothalamic prepro-QRFP mRNA expression in female rats.

Authors:  Allyson L Schreiber; Kenneth P Arceneaux; Raphael A Malbrue; Alan J Mouton; Christina S Chen; Elias M Bench; H Douglas Braymer; Stefany D Primeaux
Journal:  Neuropeptides       Date:  2016-01-26       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.